** Drug developer Septerna's shares SEPN.O fall 66.6% to $4.49 premarket
** Co discontinues an early-stage trial of its experimental drug for patients with a hormonal disorder called hypoparathyroidism
** In hypoparathyroidism patients, the body does not produce enough levels of a hormone that regulates calcium and phosphorus levels in the blood
** SEPN says it stopped the trial after two participants showed unexpectedly high levels of a substance called unconjugated bilirubin, which forms when red blood cells break down
** Says it will advance other drugs with distinct and unrelated chemical structures relative to the discontinued treatment
** Stock has fallen nearly 40% since its Nasdaq debut in October
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.